1 month ago
10
Soumya Eswaran
Thu, July 16, 2026 astatine 8:14 AM CDT 3 min read
Harris Oakmark precocious released its second-quarter 2026 capitalist missive for the "Oakmark Global Fund". A transcript of the missive tin be downloaded here. It is simply a non-diversified money that focuses connected semipermanent superior appreciation by investing successful communal stocks of U.S. and non-U.S. companies. In the 2nd quarter, the money (Investor Class) delivered a instrumentality of 7.89%, lagging the benchmark, the MSCI World Index's 13.76% return. Energy and industrials were the apical show contributors astatine the assemblage level, portion wellness attraction and user discretionary detracted from performance. AI remains a cardinal marketplace theme. The steadfast focuses connected evaluating companies based connected their competitory advantages, semipermanent currency travel potential, and valuation, not predictions. In addition, you tin cheque the Fund's apical 5 holdings to find its champion picks for 2026.
In its Q2 2026 capitalist letter, Oakmark Global Fund highlighted AstraZeneca PLC (NYSE:AZN) arsenic a recently added position. AstraZeneca PLC (NYSE:AZN) is simply a starring multinational biopharmaceutical institution focusing connected the improvement and find of medicine medicines. On July 15, 2026, AstraZeneca PLC (NYSE:AZN) closed astatine $168.37 per share, reflecting a marketplace capitalization of $261.12 billion. AstraZeneca PLC (NYSE:AZN) posted a one-month instrumentality of -3.75%, portion its shares gained 18.55% implicit the past 52 weeks.
Oakmark Global Fund stated the pursuing regarding AstraZeneca PLC (NYSE:AZN) successful its Q2 2026 capitalist update:
"AstraZeneca PLC (NYSE:AZN) is 1 of the largest pharmaceutical companies successful the world. It researches, develops and commercializes medicine medicines designed to dainty lung and bosom cancers, cardiorenal diseases, respiratory problems and different uncommon diseases. We judge AstraZeneca's robust on-market portfolio and sector-leading late-stage pipeline supply an charismatic maturation profile. Moreover, we judge the institution tin physique connected its agelong way grounds of a productive probe and improvement program, acknowledgment to its innovative civilization and exceptional absorption team. In our view, CEO Pascal Soriot is 1 of the industry's champion executives, and helium has cultivated a heavy seat of talent, a robust decision-making model and a differentiated R&D civilization that should thrust beardown maturation for years to come, successful our view. Recent concerns implicit United States regulations person overshadowed AstraZeneca's merits and weighed connected the broader pharmaceutical industry. This opened a model for america to acquisition shares of this institution astatine a terms good beneath our estimation of its intrinsic value."
.png)
English (CA) · 
English (US) · 
Spanish (MX) ·